Total Payments
$16,125
2024 Payments
$2,334
Companies
33
Transactions
734
Medicare Patients
5,392
Medicare Billing
$952,119
Payment Breakdown by Category
Food & Beverage$14,431 (89.5%)
Education$1,694 (10.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $14,431 | 668 | 89.5% |
| Education | $1,694 | 66 | 10.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| CIPLA USA INC. | $2,863 | 8 | $0 (2022) |
| Melinta Therapeutics, LLC | $2,044 | 125 | $0 (2024) |
| Astellas Pharma US Inc | $1,945 | 58 | $0 (2024) |
| Insmed, Inc. | $1,683 | 99 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,210 | 67 | $0 (2024) |
| La Jolla Pharmaceutical Company | $973.61 | 47 | $0 (2024) |
| Paratek Pharmaceuticals, Inc. | $911.98 | 55 | $0 (2024) |
| Shionogi Inc | $728.33 | 37 | $0 (2024) |
| Cumberland Pharmaceuticals, Inc. | $655.57 | 60 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $510.60 | 18 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,334 | 107 | Astellas Pharma US Inc ($518.59) |
| 2023 | $2,146 | 101 | Melinta Therapeutics, LLC ($367.18) |
| 2022 | $3,749 | 125 | CIPLA USA INC. ($1,647) |
| 2021 | $2,985 | 137 | CIPLA USA INC. ($946.20) |
| 2020 | $1,095 | 78 | Insmed, Inc. ($220.58) |
| 2019 | $1,857 | 102 | CIPLA USA INC. ($269.64) |
| 2018 | $811.54 | 37 | Melinta Therapeutics, Inc. ($236.57) |
| 2017 | $1,146 | 47 | Astellas Pharma US Inc ($293.46) |
All Payment Transactions
734 individual payment records from CMS Open Payments — Page 1 of 30
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $22.83 | General |
| Category: Respiratory | ||||||
| 12/19/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $0.81 | General |
| Category: Respiratory | ||||||
| 12/18/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $12.80 | General |
| Category: Infections and Infectious Diseases | ||||||
| 12/17/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $25.41 | General |
| 12/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | LIVTENCITY (Drug) | Food and Beverage | In-kind items and services | $47.36 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $13.05 | General |
| Category: ANTIBIOTIC | ||||||
| 12/04/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $34.53 | General |
| Category: Infectious Diseases | ||||||
| 12/04/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $15.08 | General |
| Category: Infections and Infectious Diseases | ||||||
| 12/03/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $16.17 | General |
| Category: Respiratory | ||||||
| 12/02/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $19.93 | General |
| Category: Respiratory | ||||||
| 12/02/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $18.45 | General |
| Category: ANTIBIOTIC | ||||||
| 11/27/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $19.02 | General |
| Category: Respiratory | ||||||
| 11/19/2024 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $14.61 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 11/15/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $13.81 | General |
| Category: Infections and Infectious Diseases | ||||||
| 11/14/2024 | Cumberland Pharmaceuticals, Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $13.80 | General |
| Category: INFECTIONS AND INFECTIOUS DISEASES | ||||||
| 11/13/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa, Orbactiv | Food and Beverage | In-kind items and services | $27.18 | General |
| Category: ANTIFUNGALS | ||||||
| 11/13/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa, Orbactiv | Food and Beverage | In-kind items and services | $1.06 | General |
| Category: ANTIFUNGALS | ||||||
| 11/12/2024 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $21.27 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 11/11/2024 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $15.31 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 11/11/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $14.93 | General |
| Category: ANTIBIOTIC | ||||||
| 11/07/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $21.97 | General |
| Category: Infectious Diseases | ||||||
| 11/05/2024 | Takeda Pharmaceuticals U.S.A., Inc. | LIVTENCITY (Drug) | Food and Beverage | In-kind items and services | $35.05 | General |
| Category: IMMUNOLOGY | ||||||
| 10/30/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $28.68 | General |
| Category: Infectious Diseases | ||||||
| 10/29/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $24.59 | General |
| Category: ANTIBIOTIC | ||||||
| 10/29/2024 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $15.80 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 962 | 3,999 | $433,428 | $206,473 |
| 2022 | 11 | 1,174 | 1,949 | $363,470 | $164,029 |
| 2021 | 17 | 1,594 | 9,438 | $972,645 | $324,670 |
| 2020 | 16 | 1,662 | 5,450 | $746,803 | $256,947 |
Total Patients
5,392
Total Services
20,836
Medicare Billing
$952,119
Procedure Codes
57
All Medicare Procedures & Services
57 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 441 | 994 | $149,100 | $97,070 | 65.1% |
| J2406 | Injection, oritavancin (kimyrsa), 10 mg | Office | 2023 | 14 | 2,160 | $140,400 | $66,812 | 47.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 160 | 181 | $45,250 | $11,268 | 24.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 132 | 159 | $15,900 | $10,689 | 67.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 39 | 140 | $31,500 | $6,792 | 21.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 49 | 49 | $12,250 | $6,058 | 49.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 46 | 46 | $12,650 | $4,647 | 36.7% |
| J1335 | Injection, ertapenem sodium, 500 mg | Office | 2023 | 19 | 181 | $20,943 | $1,879 | 9.0% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 16 | 35 | $2,625 | $400.52 | 15.3% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 11 | 12 | $360.00 | $352.80 | 98.0% |
| 90686 | Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | Office | 2023 | 11 | 12 | $360.00 | $258.75 | 71.9% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 13 | 16 | $1,600 | $234.90 | 14.7% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 11 | 14 | $490.00 | $10.91 | 2.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 452 | 1,014 | $152,060 | $99,173 | 65.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 333 | 409 | $102,250 | $23,167 | 22.7% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 102 | 104 | $28,600 | $11,221 | 39.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 105 | 131 | $13,100 | $8,946 | 68.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 66 | 66 | $16,500 | $8,363 | 50.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 26 | 128 | $28,800 | $6,573 | 22.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 34 | 41 | $14,350 | $3,382 | 23.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 13 | 13 | $5,200 | $2,078 | 40.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 14 | 14 | $420.00 | $403.01 | 96.0% |
| 90686 | Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | Office | 2022 | 18 | 18 | $540.00 | $377.94 | 70.0% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 11 | 11 | $1,650 | $345.41 | 20.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 443 | 946 | $141,900 | $94,951 | 66.9% |
About Dr. Fernando Alvarado, MD
Dr. Fernando Alvarado, MD is a Infectious Disease healthcare provider based in Altamonte Springs, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/21/2005. The National Provider Identifier (NPI) number assigned to this provider is 1073513958.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Fernando Alvarado, MD has received a total of $16,125 in payments from pharmaceutical and medical device companies, with $2,334 received in 2024. These payments were reported across 734 transactions from 33 companies. The most common payment nature is "Food and Beverage" ($14,431).
As a Medicare-enrolled provider, Alvarado has provided services to 5,392 Medicare beneficiaries, totaling 20,836 services with total Medicare billing of $952,119. Data is available for 4 years (2020–2023), covering 57 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Altamonte Springs, FL
- Active Since 07/21/2005
- Last Updated 12/17/2009
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1073513958
Products in Payments
- ZEMDRI (PLAZOMICIN) (Drug) $2,049
- Arikayce (Drug) $1,635
- XERAVA (Drug) $974.42
- NUZYRA (Drug) $911.98
- VIBATIV (Drug) $735.98
- Fetroja (Drug) $728.33
- Kimyrsa (Drug) $718.84
- Vabomere (Drug) $683.97
- DIFICID (Drug) $575.86
- CRESEMBA (Drug) $404.54
- Rezzayo (Drug) $382.82
- ZERBAXA (Drug) $378.22
- Cresemba (Drug) $375.18
- LIVTENCITY (Drug) $345.57
- AVYCAZ (Drug) $332.78
- CUVITRU (Biological) $263.22
- Xerava (Drug) $228.62
- ORBACTIV (Drug) $205.28
- Fibroscan (Device) $194.58
- DALVANCE (Drug) $189.38
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Altamonte Springs
Dr. Juan Diaz, D.o, D.O
Infectious Disease — Payments: $1.1M
Infectious Disease $1.1M
Jason Sniffen, Do, DO
Infectious Disease — Payments: $459,299
Infectious Disease $459,299
Christopher Cooper, Md, MD
Infectious Disease — Payments: $373,256
Infectious Disease $373,256
Javier Marinez, Md, MD
Infectious Disease — Payments: $7,961
Infectious Disease $7,961
Dr. Anibal Maldonado, M.d, M.D
Infectious Disease — Payments: $4,049
Infectious Disease $4,049
Joseph Katta, Do, DO
Infectious Disease — Payments: $2,143
Infectious Disease $2,143